Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJVC36
|
|||
| Drug Name |
A400
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Klus Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proto-oncogene c-Ret (RET) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Endocytosis | |||
| Pathways in cancer | ||||
| Thyroid cancer | ||||
| Central carbon metabolism in cancer | ||||
| Pathway Interaction Database | Signaling events regulated by Ret tyrosine kinase | |||
| Posttranslational regulation of adherens junction stability and dissassembly | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Dopaminergic Neurogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Klus Pharma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.